AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06142617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be the sequential treatment strategy at progression until resistance develops.
Study NCT04600934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Shockwave Medical, Inc. Peripheral Lithoplasty® System
Study NCT04600934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain old balloon angioplasty
Description: POBA
Study NCT06389851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Case Group - Tomato-free diet
Description: Nutritional intervention without tomatoes and sauce
Study NCT06389851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Case group - Diet enriched with tomatoes
Description: Nutritional intervention enriched with tomatoes and souce
Study NCT06230107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
Study NCT05600101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care.Coach
Description: Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates.
Study NCT06244862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
Study NCT05591326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-PRF application procedure
Description: Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
Study NCT06363565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation of compound nutrients
Description: Folic acid, vitamin B6, vitamin B12, and betaine per day orally for 12 weeks.
Study NCT06363565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of supplement.
Study NCT05228392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music
Description: listening to lullaby or other music types
Study NCT05282719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax combined with azacitidine
Description: On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
Study NCT06083350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast beta-glucan
Description: Produced by Angel Yeast Co., LTD
Study NCT06083350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Produced by Angel Yeast Co., LTD
Study NCT05866861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUG252
Description: CUG252 will be administered by subcutaneous injection.
Study NCT05866861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection.
Study NCT04694677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: women receiving tranexamic acid
Description: women receiving tranexamic acid during myomectomy
Study NCT04694677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: women receiving misoprostol
Description: women receiving misoprostol in myomectomy
Study NCT05607342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osanetant
Description: To evaluate the effect of Osanetant on the testosterone levels.
Study NCT04837807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Hydration PF
Description: This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
Study NCT04825639 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT04098276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeWomen Plus technology based intervention
Description: The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
Study NCT06250062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized IL-17A Monoclonal Antibody（JS005）
Description: Injection
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig IV (intravenous) Q3W
Study NCT06250062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo（JS005）
Description: Injection
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (intravenous) Q3W
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Study NCT04942405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TURCOVAC
Description: Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
Study NCT04942405 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
Study NCT06583564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG lymphangiography procedure
Description: All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
Study NCT06583967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Group 1 - Elliptical Trainer Group 2 - Treadmill
Study NCT05159570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Commercially available ketone supplement
Study NCT05159570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Isocaloric placebo
Study NCT04657133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
Study NCT04657133 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
Study NCT04657133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study NCT04657133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study NCT06383663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular lymph node dissection combined with radiotherapy
Description: Breast cancer patients in the expreimental cohort with only ipsilateral supraclavicular lymph node metastasis were first treated with supraclavicular lymph node dissection and received standard radiotherapy after surgery.
Study NCT06383663 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Patients in the control group received only standard radiation therapy.
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 [Tegafur/Oteracil/gimeracil]
Description: S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
Study NCT06109779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-1 [Tegafur/Oteracil/gimeracil]
Description: S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
Study NCT06185595 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.
Description: 9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
Study NCT06185595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.
Description: 9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
Study NCT05794347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traction
Description: Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
Study NCT05794347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traction
Description: Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
Study NCT04832243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
Study NCT06256861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06256861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06256861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study NCT06205225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text4HF
Description: Behavioral text messages about heart failure self-care
Study NCT06205225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyApps
Description: consumer mobile health apps and devices for heart failure self-care
Study NCT06205225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyApps & Text4HF
Description: Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
Study NCT06205225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
Study NCT05421689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
Description: The study will treat 66 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
Study NCT05421689 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: two doses of placebo will be administered and spaced 4-6 weeks apart.
Study NCT05079698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
Study NCT05079698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
Study NCT05907343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham TBS
Description: A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
Study NCT05907343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop TBS
Description: A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
Study NCT05907343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop TBS
Description: A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
Study NCT05309395 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FoodRx
Description: Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
Study NCT05309395 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FoodRx
Description: Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
Study NCT05013203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue culture
Description: Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
Study NCT05013203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
Study NCT05383456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Standard diagnostic tests.
Study NCT05383456 — intervention group
Intervention type: DRUG
Intervention: HIV Anti-retroviral Background Therapy
Description: All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study.
Study NCT06451081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief cessation advice
Description: Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again
Study NCT06451081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cessation advice
Description: Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again
Study NCT06451081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out active referral
Description: Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality
Study NCT06451081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economic mobile messaging
Description: Participants will receive behavioural economics-informed messages via mobile instant messaging for 3 months
Study NCT06451081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt-in active referral
Description: Participants will be offered a referral to a smoking cessation service. Contacts of participants who opt-in will be delivered to a service provider of their choice
Study NCT04706728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to playlists with music prior to-, during and after the ECT procedure
Description: Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
Study NCT04706728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to playlists with music prior to-, during and after the ECT procedure
Description: Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
Study NCT04706728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure
Description: Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment